Letters and drug alerts sent to healthcare professionals in November 2018
A periodic index page listing other alerts and letters, not a single alert.
Source · Drug & device safety alerts
MHRA Drug & Device Safety Alerts
1,501 individual alerts
447 medicines recalls & defect notices
766 weekly / monthly index pages
Oct 2009 – Jul 2026
Drug safety updates, medicines recalls, device safety information and field safety notices published by the Medicines and Healthcare products Regulatory Agency. Source: MHRA alerts and recalls on GOV.UK.
Showing 2,267 publications of 2,267
Medical Device Alerts issued in November 2018
A periodic index page listing other alerts and letters, not a single alert.
Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes
An article in MHRA's monthly Drug Safety Update bulletin.
Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks
An article in MHRA's monthly Drug Safety Update bulletin.
Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients
An article in MHRA's monthly Drug Safety Update bulletin.
Oral lidocaine-containing products for infant teething: only to be available under the supervision of a pharmacist
An article in MHRA's monthly Drug Safety Update bulletin.
Field safety notices - 03 to 07 December 2018
A weekly index of the field safety notices manufacturers issued that week.
Field safety notices - 26 to 30 November 2018
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Teva UK Limited and Mylan - recall of some Valsartan containing products
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Batteries for the HeartStart MRx monitor/defibrillator may fail to charge or to provide power.
Field Safety Notice - 19 November to 23 November 2018
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notice - 12 November to 16 November
A weekly index of the field safety notices manufacturers issued that week.
Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction
An article in MHRA's monthly Drug Safety Update bulletin.
Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use
An article in MHRA's monthly Drug Safety Update bulletin.
Medical Device Alerts issued in October 2018
A periodic index page listing other alerts and letters, not a single alert.
Letters and drug alerts sent to healthcare professionals in October 2018
A periodic index page listing other alerts and letters, not a single alert.
Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients
An article in MHRA's monthly Drug Safety Update bulletin.
Support Yellow Card: improve the safety of medicines in pregnancy and breastfeeding, and in babies and children
An article in MHRA's monthly Drug Safety Update bulletin.
Mitomycin-C Kyowa: Company-led Drug Alert
A recall the marketing authorisation holder initiated, published by MHRA.
Field Safety Notice - 05 November to 09 November
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notice - 29 October to 02 November
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notice - 22 October to 26 October
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notice - 15 October to 19 October
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notice - 8 October to 12 October
A weekly index of the field safety notices manufacturers issued that week.
Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
An article in MHRA's monthly Drug Safety Update bulletin.
Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
An article in MHRA's monthly Drug Safety Update bulletin.
Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial
An article in MHRA's monthly Drug Safety Update bulletin.
Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children
An article in MHRA's monthly Drug Safety Update bulletin.
Medical Device Alerts issued in September 2018
A periodic index page listing other alerts and letters, not a single alert.
Letters and drug alerts sent to healthcare professionals in September 2018
A periodic index page listing other alerts and letters, not a single alert.
Field Safety Notice - 1 October to 5 October
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Ozurdex 700 micrograms intravitreal implant in applicator manufactured by Allergan Pharmaceuticals Ireland (MDR 95-08/18)
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notice - 24 September to 28 September
A weekly index of the field safety notices manufacturers issued that week.
Daclizumab beta (Zinbryta▼): risk of immune-mediated encephalitis – some cases several months after stopping treatment
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and drug alerts sent to healthcare professionals in August 2018
A periodic index page listing other alerts and letters, not a single alert.
Nusinersen (Spinraza▼): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently
An article in MHRA's monthly Drug Safety Update bulletin.
Xofigo▼ (radium-223-dichloride): new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial
An article in MHRA's monthly Drug Safety Update bulletin.
Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notice - 17 September to 21 September
A weekly index of the field safety notices manufacturers issued that week.
Imatinib 400mg Capsules (3 x 10) PL 36390/0180 : Company-led Drug Alert
A recall the marketing authorisation holder initiated, published by MHRA.
Class 4 defect information: Caspofungin 70mg powder for concentrate for solution for infusion (MDR 11-09/18)
Field Safety Notice - 10 September to 14 September
A weekly index of the field safety notices manufacturers issued that week.
Mydriasert 0.28mg/5.4mg Ophthalmic Insert: Company-led recall
Field safety notices - 03 to 07 September 2018
A weekly index of the field safety notices manufacturers issued that week.
Class 4 defect information: Olmetec 20mg Film Coated Tablets (MDR 12-08/18)
Field Safety Notice - 28 to 31 August
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notice - 20 to 24 August
A weekly index of the field safety notices manufacturers issued that week.
Esmya (ulipristal acetate) and risk of serious liver injury: new restrictions to use and requirements for liver function monitoring before, during, and after treatment
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and drug alerts sent to healthcare professionals in July 2018
A periodic index page listing other alerts and letters, not a single alert.
Medical Device Alerts issued in July 2018
A periodic index page listing other alerts and letters, not a single alert.
About this source
Individual alerts by type
Read the chart values
| Alert type | Individual alerts |
|---|---|
| Drug Safety Update | 713 |
| Class 1 Medicines Recall | 6 |
| Class 2 Medicines Recall | 159 |
| Class 3 Medicines Recall | 68 |
| Class 4 Medicines Defect Information | 179 |
| Company-Led Medicines Recall | 35 |
| Device Safety Information | 21 |
| Medical Device Alert | 40 |
| National Patient Safety Alert | 11 |
| MHRA Safety Roundup | 16 |
| Unclassified | 253 |
The MHRA regulates medicines and medical devices in the UK and publishes safety communications on GOV.UK in two streams: the monthly Drug Safety Update bulletin, and Alerts and recalls for drugs and medical devices. This page holds 2,267 of those publications, issued between October 2009 and July 2026.
MHRA classes a medicines recall by the hazard the defect presents: Class 1 life-threatening or serious, Class 2 could cause illness or mistreatment, Class 3 unlikely to cause harm, and Class 4 a caution in use rather than a recall, with the product staying available. A device notice is published as Device Safety Information, or, until 2021, as a Medical Device Alert.
What is not here. We hold each publication's title, type, date and link, not its text: read the alert on GOV.UK for the affected products and the actions MHRA asks for. An alert names a medicine or device and a clinical audience, not an organisation, so no alert on this page is linked to an NHS trust or other responsible body. The weekly “Field Safety Notices” pages are MHRA's own index of the notices manufacturers issued that week, not single alerts, and are counted separately above.